Gorbec Pharmaceutical Services, a rapidly expanding contract developer and manufacturer of prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory in Yantai, China. This new facility will expand Gorbec\'s current services for analytical method development and testing. Gorbec is taking this action to better serve its U.S. customer base as well as develop a presence in the emerging Asian market.
Gorbec currently provides complete development, regulatory, analytical, and manufacturing services for U.S.-based customers. Gorbec\'s future plans call for an increased capacity to develop and submit New Drug Applications (NDA\'S) and will require an expansion of analytical services. In an effort to improve efficiencies and reduce costs, the company has elected to locate the new analytical facility in China. The company\'s core business services, current analytical laboratory, and commercial manufacturing will remain in the U.S. The China facility is expected to open May 1st, 2010 but Gorbec is already working with customers who have plans to use some of the new facility\'s capacity.
The Yanti facility will operate under the direction of Gorbec\'s Vice President of Analytical Chemistry, Dr. Jing Chen. Dr. Chen received her PhD from Stanford University and brings a wealth of pharmaceutical experience to the operation. She joined Gorbec after holding various positions at Genentech Inc. and Alza Corporation. Working with Dr. Chen will be Yan Zhang who will oversee the daily operations locally in Yantai.
Gorbec\'s Founder and CEO, Mike Gorman added, \"We are very excited about our future and our ability to offer a GMP laboratory in China. This new location will allow us to serve our own needs as well as the needs of companies looking to develop and distribute pharmaceutical products for the Asian Market.\"
About Gorbec
Gorbec Pharmaceutical Services, Inc. is a privately held company providing complete pharmaceutical development and manufacturing services. Gorbec\'s highly experienced management team has driven the company to become a leader in the field of cGMP contract manufacturing services. The company is focused primarily on the development of new drugs products that fill specialty niches within the traditional segment of the pharmaceutical business.